
Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

Vera Pomerantseva is Director of Product Management, RBQM, at eClinical Solutions. Vera has over 20 years of pharma industry and business consulting experience in quality and risk-based quality management (RBQM), leading innovations, and data analytics. Experienced in driving strategy and leading design and implementation efforts, she has a proven track record of success in leading a variety of R&D projects, including RBQM. Prior to joining eClinical Solutions, Vera was Associate Partner at ZS, after spending 20 years in big pharma including Novartis and Bristol Myers Squibb. She is a published author and member of various industry groups. Vera holds a Master of Science in Management and Post Graduate Certificate in Risk Management from State University of Management, Moscow, along with a certification in Clinical Trials Management from UC Berkeley.

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

Because of drastic changes in the clinical trial space, there is a need for advancing and streamlining design through risk-based methodologies and innovations.

How optimizing RBQM risk detection reduces the efforts caused by false signals.

Developing a higher level of critical thinking can create a comprehensive risk story and properly direct mitigations throughout your organization.

Applied Clinical Trials
RBM is an emerging area which gives endless opportunities to explore, transform, and evolve.

Applied Clinical Trials
Proper questionnaire coding and design can help set the stage for a successful trial.

September 7th 2022

March 1st 2012

December 27th 2018